期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多西他赛与顺铂联合化疗治疗复发进展期非小细胞肺癌临床研究 被引量：10

在线阅读 下载PDF
导出
摘要 目的研究多西他赛与顺铂联合化疗治疗复发进展期非小细胞肺癌患者的疗效和毒副反应。方法共入选69例,采用第1天,多西他赛60mg/m2,第2天或分次给药,顺铂70～75 mg/m2,每3～4周为1个周期,连用2～4个周期。结果 8例因化疗毒副反应只进行1个周期化疗而无法评价疗效;部分有效14例,总有效率23.0%(14/61例),疾病控制率59.0%(36/61例),1年生存率14.5%(10/69例),中位生存期6.4个月。69例均可评价毒副反应,白细胞及中性粒细胞下降100%,Ⅲ度以上白细胞及中性粒细胞减少分别为81.2%(56/69例)、88.4%(61/69例),中性粒细胞减少性发热34.8%(24/69例),贫血及血小板下降以Ⅰ、Ⅱ度为主。结论多西他赛与顺铂联合化疗治疗复发进展期非小细胞肺癌患者有效,剂量限制毒性为粒细胞减少,毒副反应高可耐受。
作者 孟弃逸 李明智 仝丽 郭丽丽 武伟 唐俊舫 徐丽艳 刘喆
机构地区 首都医科大学附属北京胸科医院 北京肺癌诊疗中心
出处 《中国临床医生杂志》 2012年第7期51-53,共3页 Chinese Journal For Clinicians
关键词 多西他赛 复治 晚期非小细胞肺癌 铂类 联合化疗
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Non small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomized clinical trials [ J ]. BMJ, 1995,311: 899 -909.
  • 2Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non small cell lung cancer previously treated with platinum-based chemotherapy [ J ]. J Clin 0ncol,2000,18:2095 - 2103.
  • 3Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase IlI trail of pemetrexed versus docetaxol in patients with non small cell lung cancer previously treated with chemotherapy [ J ]. J Clin Onco1,2004,9: 1579 - 1589.
  • 4Zubrod CG, Schneidermann M, Frei M, et al. Appraisal ofmethods for the study of' chemotherapy of cancer in man : Compar- ative therapeutic trial of nitrogen mustard and triathlon thiophos- phoramide[ J ]. J Chron Dis, 1960,11:7 - 33.
  • 5朱尧武,杨宇飞.肺癌的疗效评定[J].中国临床医生杂志,2001,29(12):21-22. 被引量：1
  • 6Schiller J H, Harrington D, Belani C P,et al. Comparison of four chemotherapy regimens for advanced non small cell lung cancer I J ]. N Engl J Med ,2002,346: 92 - 98.
  • 7Frank Fossella, Jose R Pereira, Joachim yon Pawel, et al. Ran- domized, Multinational, Phase 111 Study of docetaxel plus cis- platinum combinations versus vinorebine plus cisplatin for ad- vanced non-small cell lung cancer [J]. The TAX326 Study Group J Clin Onco1,2003,21 (16) : 3016 - 3024.
  • 8Cesare Gridelliet. Results and recommedations of second line therapy of non small cell lung cancer: Prognosis and aim[ J]. J Thora Oneo1,2008,3 (4) : 1268 - 1275.
  • 9袁蕾,洛淼,李德爱.肺癌化疗后骨髓抑制危险因素分析[J].中国医刊,2010,45(3):57-58. 被引量：6
  • 10Hutchins LF, Unger JM, Crowley JJ. Underrepresentation of pa- tients 65 years of age or older in cancer treament trials [ J ]. N Engl J Med, 1999,3gl : 2061 - 2070.

二级参考文献5

  • 1刘秋菊,姜玉珍,贾姣源.化疗后骨髓抑制危险因素分析[J].江西医学院学报,2005,45(3):48-50. 被引量：20
  • 2何建萍,易成,鄢希,任莉,李潞,罗德云,侯梅,毕锋,谢名英.有无吸烟史的晚期非小细胞肺癌4种化疗方案的临床比较[J].中国药业,2007,16(15):44-45. 被引量：4
  • 3Anderson H, Hopwood P, Stephens RJ, et al. Gemeitabine/plos beat supportive care vs BSC in inoperable non-small cell lung cancera ram-domized trial with quality of life as the primary outcome [ J ]. Br J of Cancer, 2000, 83:447 -453.
  • 4Shepherd F A, Dancey J, Ramlan R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy [J]. J Clin Oncoly, 2001, 18(12):2095 -2103.
  • 5Howard O. New directions in the management of chemotherapy-induced neutroprnia: Risk models, specialpopulations, and quality of life [ J ]. Semin oncology,2003, 30 (4 Suppl 13 ) : 18.

共引文献5

同被引文献113

  • 1聂立功,王广发.肺癌的个体化治疗[J].中国医学前沿杂志（电子版）,2014,6(2):17-18. 被引量：12
  • 2刘春秋,李国欢,赵洪焕,王翠兰,韩素桂,杨俊泉.放化治疗非小细胞肺癌p53抗体检测价值[J].中国医学前沿杂志（电子版）,2014,6(3):35-38. 被引量：6
  • 3勾红峰,陈心传,侯梅,杨雨.GP和TP方案治疗晚期非小细胞肺癌的随机对照临床研究[J].中国肺癌杂志,2007,10(2):141-143. 被引量：13
  • 4周志孝,王中和.“减时增量”技术提高放疗的肿瘤控制率[J].中华临床医学卫生杂志,2007,5(4):28-30. 被引量：1
  • 5Shimosato Y. Histological Typing of Lung and Pleural Tumors (3rd edition, 1999 ) : Malignant epithelial tumors [ J ]. Nihon Rinsho, 2002,60( Suppl 5 ) :123-131.
  • 6De Giacomo T, Venuta F, Rendina EA. Role of lymphadenectomy in the treatment of clinical stage I non-small cell lung cancer[J]. Tho- rac Surg Clin, 2007, 17:217-221.
  • 7Cadili A, Scolyer RA and Brown PT. Total sentinel lymph node tumor size predicts nonsentinel node metastasis and survival in pa- tients with melanoma[ J]. Ann Surg Oneol, 2010,17:3015-3020.
  • 8Zou W. Regulatory T cells, tumor immunity and immunotherapy (review) [J]. Nat Rev Immuno, 2006, 6(4) :295-307.
  • 9Beyer M, Kochanek M, Darabi K, et al . Reduced frequencies and suppressive function of CD CD25 regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine [ J ] . Blood, 2005, 106(6) :2018-2025.
  • 10Moeller B J, Dewhirst MW. HIF-1 and tumour radiosensitivity [ J ]. Br J Cancer,2006,95 ( 1 ) :1-5.

引证文献10

二级引证文献94

中国临床医生杂志
2012年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部